GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities
GlaxoSmithKline (GSK; NYSE: GSK) announced today a $30 billion U.S. investment program that will fund research...
Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound
Novo Nordisk A/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a...
Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere
InnoBM Pharmaceuticals Co., Ltd. and Qilu Pharmaceutical Co. have inked a collaboration agreement to commercialize...
Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche
Henlius Biotech Inc. (HKG: 2696) is reportedly in talks with global pharmaceutical giants Johnson & Johnson (J&J,...
Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board
Shenzhen Mindray Bio‑Medical Electronics Co. has confirmed that Huatai Securities and JPMorgan Chase & Co. are the...
Duoning Bio Secures Global License for Upstream Bio’s Biochemical Analyzer Portfolio
Duoning Biotechnology Co., Ltd. announced a strategic partnership with Upstream Bio Inc., granting Duoning an...
CSPC’s ALMB-0166 Approved for Phase II Trials in Parkinson’s Disease
CSPC Pharmaceutical Group Limited (HKG: 1093), a China-based company, announced on September 15, 2025, that...
Nanjing Leads Biolabs Doses First Patient in Opamtistomig Melanoma Trial
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the first patient has been...
AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the launch of Ultomiris (ravulizumab), a...
AstraZeneca Pauses GBP 200m Cambridge R&D Investment Amid UK Funding Cuts
On September 12, 2025, AstraZeneca (AZ; NASDAQ: AZN) confirmed it has paused its GBP 200m...
Novo Nordisk Rybelsus Gains Cardio Benefit from SOUL Trial
Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products...
Guangzhou Baiyunshan Pharmaceutical Launches Phase I/II Trial for RET‑Targeted BYS10
Guangzhou Baiyunshan Pharmaceutical Co., Ltd. (SHA: 600332) announced that the Center for Drug Evaluation (CDE)...
Sino Biopharmaceutical Secures NMPA Approval for Degarelix Generic in China
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis‑Related Pruritus
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration...
Monte Rosa Therapeutics and Novartis Partner on Degrader Development
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS)...
Fovinaciclib CDK4/6 Breaks Ground in Breast‑Cancer Therapy
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Avanc...
Shenzhen Kangtai Receives NMPA Approval for Sabin‑Strain Inactivated Polio Vaccine
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced today that the China National Medical...
BioRay Biopharmaceutical Secures NMPA Approval for BGM0504 in Overweight/Obesity Trials
BioRay Biopharmaceutical (SHA: 688166) announced today that its dual‑agonist drug BGM0504 has received National Medical...
Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a...
Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application
Shanghai‑based Rona Therapeutics Inc. announced on September 15, 2025 that it has formally submitted a Clinical Trial...